Medical Prior Auth Compliance Engineering.

CMS-0057-F (89 FR 8758, published January 17, 2024) requires affected payers to support four FHIR-based APIs: a Prior Authorization API combining the Da Vinci CRD, DTR, and PAS workflows; a Patient Access API for USCDI clinical data, claims, and PA information; a Provider Access API for in-network treating providers; and a Payer-to-Payer API for plan transitions. PA decision timeframes are 72 hours expedited and 7 calendar days standard (reduced from 14). Specific clinical denial reasons are required (not generic form language). Affected payers must publish PA performance metrics annually starting March 31, 2026 for CY 2025. The FHIR PA API compliance date for Medicare Advantage and Medicaid/CHIP FFS is January 1, 2027.

CMS-0062-P (Drug PA Proposed Rule, March 2026) extends CMS-0057-F in several medical-PA-relevant ways. QHP issuers on FFEs come into alignment with MA and Medicaid decision timeframes (7 days standard, 72 hours expedited) effective October 1, 2027. Medical benefit drugs are brought into the scope of the FHIR Prior Authorization API. Updates to the four APIs add drug-specific fields. FHIR is being elevated from a discretionary alternative to a HIPAA-mandated standard for PA (replacing the X12 278 enforcement discretion currently in effect). Pharmacy benefit drug PA components (NCPDP SCRIPT ePA, F&B, RTPB) are out of scope for this whitepaper and will be covered in a forthcoming dedicated Rx PA whitepaper.

Six payer categories: Medicare Advantage organizations; state Medicaid Fee-for-Service programs; Medicaid managed care plans; state Children’s Health Insurance Program (CHIP) Fee-for-Service programs; CHIP managed care entities; and Qualified Health Plan (QHP) issuers on Federally-facilitated Exchanges. CMS-0062-P expands the regulatory reach by adding CHIP-specific accommodations and aligning QHP FFE non-drug PA timeframes with the MA / Medicaid floor.

The architectural commitment that AI never issues a clinical adverse determination unilaterally. Auto-affirmation is permitted; auto-denial is not. Every clinical non-affirmation routes to a licensed human clinical reviewer with full evidence pre-assembled. The commitment satisfies the CMS WISeR Innovation Model’s explicit prohibition on AI-only adverse determinations, the CMS MA Final Rule’s parallel prohibition for Medicare Advantage, and state AI laws (Colorado SB24-205, California SB 1120). It is architecturally enforced in the Healthcare Brain, not policy-enforced, and cannot be configured around.

Affected payers must publish prior authorization performance metrics annually, beginning March 31, 2026 for CY 2025 non-drug PA. Required metrics include approval rate, denial rate, time-to-decision distributions, and appeal outcomes. CMS-0062-P proposes adding drug-specific PA metrics starting in 2028 for CY 2027 reporting, plus expanded API usage metrics. The public reporting is what converts CMS-0057-F from a compliance obligation into a reputational mechanism: payer performance is comparable, measurable, and visible to providers, regulators, and members.

Genzeon Platforms operates the only commercial AI Participant in a CMS Innovation Center model in production today, under the CMS WISeR program. Live since January 1, 2026 in MAC JL (New Jersey) with Novitas Solutions. Q1 2026 processed over 15,000 Medicare prior authorization cases at 100% compliance with the federal three-day turnaround standard. Sub-three-minute median decision latency on the auto-affirm path. Zero auto-denials issued. 42% clinical reviewer productivity gain. Every non-affirmation routed to a licensed human reviewer with full evidence pre-assembled. This is what the operational floor CMS-0057-F now sets for the broader payer ecosystem looks like in production.

Twelve patents filed under USPTO Customer Number 226167, with approximately 346 claims locked at priority dates. All claims are assigned to Genzeon Corporation. The portfolio protects the architectural pattern itself (three-tier agentic coordination), the specific mechanisms inside it (atomic criteria decomposition, cross-context inference, dual verification gate, no-auto-deny enforcement, deterministic gate decisioning), and the supporting infrastructure (multi-channel submission orchestration, ambient agent integration, distributed threshold cryptography). The Agentic Knowledge Pack Specification (AKPS) is released as an open standard; the proprietary Pack Engine that executes it is patent-protected. Customers licensing the Healthcare Brain receive both the substrate and the IP rights to operate it. A payer planning an in-house build addressing comparable architectural ground should plan for IP review.

The Healthcare Brain (or any comparable substrate) can sit in front of an existing UM workflow at the administrative pre-screening layer — eligibility verification (270/271), submission completeness checks, duplicate detection, document classification, coding accuracy checks — routing the cleanly-prepared cases through the existing criteria engine. The substrate extends the stack rather than replacing it. The medical-necessity layer continues to run through the customer’s licensed criteria sets (MCG, InterQual, or the payer’s own coverage policies) under existing licensing agreements. Integration with proprietary criteria sets is available where the customer holds an active license and the criteria publisher has authorized programmatic use.

For payers building in-house from a standing start, the typical timeline is 18–30 months to a production-grade FHIR PA API surface, audit ledger, and human-in-the-loop pathway. For payers licensing a substrate (whether the Healthcare Brain or a comparable solution), commercial deployments outside federal regulatory contexts typically reach production in 12–16 weeks for cloud-native deployments and somewhat longer for sovereign on-premises. Genzeon Platforms went from CMS WISeR contract award to live Medicare prior authorization production in approximately six months, with full federal regulatory oversight in place.

CMS-0057-F became effective in stages. January 1, 2026: PA decision timeframes (72 hours expedited, 7 calendar days standard), specific clinical denial reasons, and metric collection in force. March 31, 2026: first public non-drug PA performance metrics due for CY 2025 (recurring annually). January 1, 2027: FHIR Prior Authorization API compliance deadline for Medicare Advantage and Medicaid/CHIP Fee-for-Service. 2027 rating periods on/after January 1: Medicaid managed care, CHIP managed care, and QHP FFE FHIR APIs operational. March 31, 2027: first Patient Access API usage metrics due for CY 2026.

CMS-0057-F sets two PA decision timeframes for affected payers. Expedited: 72 hours (3 calendar days) from receipt for PA requests where waiting could seriously jeopardize the enrollee’s life, health, or ability to regain maximum function. Standard: 7 calendar days (reduced from the prior 14-day baseline) for routine PA requests. Both timeframes are wall-clock time, not business days. The timeframes have been in effect since January 1, 2026. CMS-0062-P aligns QHP FFE issuers to the same timeframes effective October 1, 2027.

Effectively yes. CMS-0057-F requires affected payers to support four FHIR-based APIs (Prior Authorization, Patient Access, Provider Access, Payer-to-Payer) using HL7 FHIR R4 as the mandatory technical standard under 45 CFR 170.215. The HHS National Standards Group memo of February 28, 2024 established enforcement discretion for the legacy X12 278 standard when entities use FHIR-based PA APIs. CMS-0062-P proposes elevating FHIR to a HIPAA-mandated administrative standard, with 24-month and 36-month adoption timelines for covered entities and small health plans respectively.

The major non-impacted categories are Medicare Fee-for-Service (administered directly by CMS via MACs), commercial fully-insured plans not on FFEs, and self-insured ERISA plans. The CMS-0057-F regulatory perimeter is: Medicare Advantage organizations, state Medicaid Fee-for-Service, Medicaid managed care, CHIP Fee-for-Service, CHIP managed care entities, and QHP issuers on Federally-facilitated Exchanges. CMS-0062-P does not change this perimeter directly but adds CHIP-specific accommodations and brings QHP FFE issuers fully into PA timeframe alignment.

Affected payers must publish prior authorization performance metrics annually, recurring. The first non-drug PA metrics were due March 31, 2026 for CY 2025. Required metrics include: percentage of PA requests approved, percentage denied, average and median time to decision, approval rate after appeal, denial rate after appeal, and breakdowns by service category. CMS-0062-P proposes adding drug-specific PA metrics starting in 2028 for CY 2027, plus expanded API usage metrics covering Patient Access, Provider Access, and Payer-to-Payer.

CMS-0057-F is a final rule (89 FR 8758, published January 17, 2024). It is the operational baseline for medical (non-drug) prior authorization. CMS-0062-P is a proposed rule issued in March 2026, extending CMS-0057-F to cover drug prior authorization plus several medical-PA-relevant provisions. The medical-PA components of CMS-0062-P include QHP FFE timeframe alignment, medical-benefit drugs entering the FHIR PA API, FHIR adoption under HIPAA, and updates to the four APIs for drug fields. The pharmacy-benefit drug PA components (NCPDP SCRIPT ePA, F&B, RTPB) are out of scope for this whitepaper.

The FHIR Prior Authorization API mandate takes effect January 1, 2027 for Medicare Advantage organizations and Medicaid/CHIP Fee-for-Service programs. For Medicaid managed care plans, CHIP managed care entities, and QHP issuers on FFEs, the deadline is 2027 rating periods on or after January 1 — meaning per-plan effective dates that vary by state but converge on calendar-year boundaries. Affected payers should plan their FHIR PA API build to land production-ready by the earliest applicable date for their category.

Yes, for now. The HHS National Standards Group memo of February 28, 2024 established enforcement discretion for the HIPAA-mandated X12 278 standard when entities use FHIR-based PA APIs. This means payers using FHIR for PA submission do not face HIPAA enforcement action for not supporting X12 278 in parallel. CMS-0062-P proposes changing this by elevating FHIR to a HIPAA-mandated standard, eliminating the discretion structure. The timeline is 24 months post-effective for covered entities, 36 months for small health plans. Payers building today should treat FHIR-as-mandated as the forward-looking certainty.

CMS-0057-F non-compliance creates several distinct exposure surfaces. Direct regulatory action: CMS may apply civil monetary penalties, contract sanctions for Medicare Advantage organizations, and contract terminations in severe cases. Reputational exposure: the public reporting requirement converts non-compliance into a publicly visible metric, comparable across payers, consumed by regulators, providers, and members. Operational exposure: non-compliant PA processes that delay determinations beyond the 7-day standard or 72-hour expedited window expose payers to provider and member complaints, state insurance commissioner attention, and litigation risk. CMS is expected to publish specific enforcement guidance as the public reporting cycle matures.